Phase
Condition
Rheumatoid Arthritis
Dermatomyositis (Connective Tissue Disease)
Arthritis And Arthritic Pain
Treatment
conventional synthetic antirheumatic drugs
Nicotinamide Tablet
Clinical Study ID
Ages 18-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Adult patients (18-65 years).
Patients with a diagnosis of established rheumatoid arthritis.
Patients presenting with moderate to high disease activity identified as diseaseactivity score-28 based on C-reactive protein levels (DAS-28-CRP) >3.2.
Receiving stable regimen of one or more conventional disease modifying antirheumaticdrugs for at least the past three months.
Patients willing to sign an informed consent.
Exclusion
Exclusion Criteria:
Patients with a known history of hypersensitivity or drug allergies to nicotinamide
Patients receiving nicotinamide for any other indications.
Receiving any dosage forms/ dosage regimen of vitamin B3 supplementation
Receiving biologic disease modified antirheumatic drugs therapy.
Impaired liver functions (liver transaminases level ≥ three times upper normallimits).
Impaired kidney functions (estimated glomerular filtration rate (eGFR) < 30 ml/min)
Pregnancy and lactation.
Patients with other auto-immune diseases.
Study Design
Study Description
Connect with a study center
Ain Shams University Hospitals
Cairo,
EgyptActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.